Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

July 22, 2024 — The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

Southwest United Graduate School, Yunnan Key Laboratory of Cell Metabolism and Diseases, State Key Laboratory of Conservation and Utilization of Bio-resources in Yunnan Center for Life Sciences, ...

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

The field of cancer research is rapidly evolving, with a growing focus on the intersection of cancer immunology, gene editing, and epigenetics. This ...

New study reveals that TLE6 protein deficiency causes male infertility in mice. These findings suggest potential genetic ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Epidermal growth factor receptor (EGFR) is a major driver of cancer dissemination and target for anti-cancer therapies but ...

By 2025, innovations such as lab-on-a-chip technology, automation, and CRISPR-Cas9 gene editing are expected to enhance ...